Frontline Doctors and Hydroxychloroquine (2022)

Hydroxychloroquine Treatment Protocols

Hydroxychloroquine is part of the FLCCC's I-CARE treatment protocol and the Zelenko treatment protocol for COVID-19. For details, click on the links above.

Hydroxychloroquine (HCQ) is more effective when given early vs late (62% vs 19% improvement) (R). Early treatment consistently shows positive effects. Negative evaluations typically ignore treatment time, often focusing on a subset of late stage studies or dosages that are given too high with associated side effects.

As of October 2022 there have been more than 30 studies of Hydroxychloroquine for early treatment with an overall average improvement of 62% as compared to the control groups.

Here’s a chart from c19early.com that shows that hydroxychloroquine performs better than ivermectin when given as early treatment in terms of risk reduction of dying from COVID-19:

The overall improvement for hydroxychloroquine is better than ivermectin (for early treatment); 72 % vs 40 % in terms of risk of death reduction. Importantly, hydroxychloroquine needs to be given 'early'.

The evidence tracking on Hydroxychloroquine versus COVID-19 is available at c19hcq.com (constantly updated).

Editor's Note: But will hydroxychloroquine be effective against omicron? Do take note that most of the published studies are based on patients recruited during the pre-omicron era. Therefore, we can't simply assume that it might work for the omicron variant and subvariants.

Unlike in March 2020 when HCQ was first suggested as a treatment, we currently have plenty of drugs to treat COVID including antivirals, such as paxlovid and molnupiravir, anti-inflammatories, such as dexamethasone, and antibody therapies.

Hydroxychloroquine Map

Below are the US map and the world map which show how difficult or easy it is to obtain HCQ throughout the world. (Source)

Read More: https://americasfrontlinedoctors.org/covid/hydroxychloroquine/